{"id":"W4400272924","doi":"10.1200/jco.2024.42.16_suppl.tps4203","title":"Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; FOLFIRINOX; Atezolizumab; Pancreatic ductal adenocarcinoma; Oncology; Internal medicine; Open label; Stage (stratigraphy); Pancreatic cancer; Randomized controlled trial; Oxaliplatin; Cancer; Nivolumab; Colorectal cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001804991,0.0002382556,0.001742484,0.0001593699,0.00003467357,0.00004648103,0.0004091445,0.0001073878,0.00002810323],"category_scores_gemma":[0.0006886118,0.0001417183,0.0001634793,0.0001999439,0.0002768825,0.00003499299,0.000190332,0.0004665242,0.000002340942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009320163,"about_ca_system_score_gemma":0.000990866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000428463,"about_ca_topic_score_gemma":0.001345047,"domain_scores_codex":[0.9958832,0.001194549,0.001761653,0.0003955025,0.0004548655,0.0003102852],"domain_scores_gemma":[0.9974924,0.000680957,0.0008995003,0.0003119958,0.0003563773,0.0002587076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8103674,0.04412998,0.1320319,0.0000892583,0.004926981,0.00210941,0.0002091241,0.0001874482,0.0001422977,0.00003559162,0.0001202586,0.005650348],"study_design_scores_gemma":[0.8284115,0.1527909,0.01594055,0.0001458703,0.001005555,0.00002487619,0.0003291818,0.0007742487,0.0002303217,0.00004563501,0.0001264502,0.0001749754],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965858,0.0009984123,0.0001355642,0.0001030391,0.000192606,0.001746878,0.00003385923,0.000003404789,0.0002004046],"genre_scores_gemma":[0.998726,0.0002012737,0.00069965,0.00005910636,0.0000734309,0.0000632012,0.00004070229,0.00003179402,0.0001048052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1160913,"threshold_uncertainty_score":0.5779104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08772171573927955,"score_gpt":0.4636311883234602,"score_spread":0.3759094725841807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}